Cannabis “benefits patients with inflammatory bowel disease (IBD), According to a new study published in the United European Gastroenterology Journal, and epublished by the National Institute of Health.
According to a new case report a patient with a multi-year history of chronic pain and opioid use was weaned off prescription opiates following the use of medical cannabis. The report, titled Medical cannabis as an alternative for opioids for chronic pain: A case report, was published by Medical Case Reports.
According to new survey data published in the journal Complimentary Therapies in Medicine a epublished by the National Institute of Health, the majority of physicians-in-training in Canada say that they receive insufficient instruction with regard to the use of cannabis for therapeutic purposes.
The legalization of marijuana for recreational use is associated with an increase in home values. This is according to a new study published by the Social Science Research Network. The study is titled Retail marijuana deregulation and housing prices.
For the study researchers examined the relationship between marijuana legalization and regional home values.
According to a new study published in the journal Phytotherapy Research, the sustained use of marijuana in patients with chronic conditions is associated with quality of life maintenance and a lack of cognitive decline. The study, titled Quality of life, mental health, personality and patterns of use in self-medicated cannabis users with chronic diseases: A 12-month longitudinal study, was also published by the National Institute of Health.
According to a new study published in the Journal of Palliative Medicine, the adjunctive use of marijuana is associated with opioid-sparing effects and overall improvements in symptom management in those suffering from cancer pain. The study is titled The efficacy of medical marijuana in the treatment of cancer-related pain.
For the study, researchers examined trends in opioid consumption and symptom control in cancer patients who did and did not consume marijuana for medical purposes. Their objective states: “We sought to characterize MMJ’s role on symptomatic relief and opioid consumption in the oncologic population.”
Among those who use marijuana on a regular basis, smoking remains their top consumption method of choice. This is according to a new study conducted by the United States Centers for Disease Control (CDC) and published in the journal Drug and Alcohol Dependence: It was also published by the National Institute of Health.
According to a new study published in the journal Trauma Surgery & Acute Care, trauma patients who are administered THC capsules consume fewer opioids than do similarly matched control subjects. The study is titled Matched pilot study examining cannabis-based dronabinol for acute pain following traumatic injury.
For the study researchers examined the off-label use of dronabinol (which is an FDA-approved synthetic oral THC) on opioid consumption patterns in trauma patients with acute pain. 66 patients participated in the study: Half received THC, and the other half did not.
The use of marijuana is increasing at a rapid pace among those aged 65 and older, according to a new study published on February 24, 2020 in the journal JAMA Internal Medicine.
“With the legalization of cannabis in many states for medical and/or recreational purposes, there is increasing interest in using cannabis to treat a variety of long-term health conditions and symptoms common among older adults”, states the study. “The use of cannabis in the past year by adults 65 years and older in the United States increased sharply from 0.4% in 2006 and 2007 to 2.9% in 2015 and 2016.”
Those with sickle cell disease (SCD) who consume cannabis on a daily basis have lower rates of hospital admissions than do similarly matched individuals who don’t use cannabis. This is according to a new study published in the journal Cannabis and Cannabinoid Research.
For the study, researchers from Yale School of Medicine and the Medical College of Wisconsin “performed a cross-sectional study of adults with SCD and compared daily users of cannabis with others using validated patient-reported measures of pain and quality of life as well as opioid and health care utilization.”